Generex Biotechnology Announces the Appointment of Chief Commercial Officer
March 12 2019 - 09:14AM
InvestorsHub NewsWire
Generex Biotechnology Announces the Appointment of Chief Commercial
Officer
Lance Goudzwaard Appointed to Head
Commercialization and Customer Relations for NuGenerex Distribution
Solutions Subsidiary
MIRAMAR, FL -- March 12, 2019 -- InvestorsHub NewsWire --
Generex Biotechnology Corporation (www.generex.com) (OTCQB:
GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is proud to
announce the appointment of Lance Goudzwaard as the Chief
Commercial Officer for NuGenerex Distribution Solutions (NDS), the
company’s wholly-owned subsidiary. Mr. Goudzwaard will be
responsible for the delivery and operation of the management
services organization (MSO) platform that is currently operational
in five states, with an aggressive growth strategy designed to
expand the model to 27 states in the next several months. Mr.
Goudzwaard will also focus on building and developing our durable
medical equipment (DME) service offering called DME-IQÔ, a software
system being introduced to the orthopedic market with turnkey
services to support the development and management of compliant and
profitable in-office DME programs. The NDS DME-IQ program includes
vendor negotiations to decrease cost of goods (COGs), oversight of
coding during the billing process, management of the appeals
process using patient focused support personnel to improve
insurance collections, and technology enabled systems that ensure
compliance with state and federal regulations.
“We are extremely proud to have Lance, a highly regarded thought
leader in the field of practice management, joining our team,” said
Terry Thompson, COO of Generex and President of NuGenerex
Distribution Solutions. “In his role, Lance will work with the
NuGenerex family of companies to expand the company’s portfolio of
ancillary health services while advancing the corporate mission to
provide end-to-end solutions for physicians and patients, leading
our client services team, MSO operations, and new product
introductions. His vast experience and extensive network will truly
enhance the strength of the NDS operation.”
Mr. Goudzwaard has built a 25+ year career in healthcare as a
senior executive implementing operational strategies that result in
high impact sales, new business development, and organizational
profitability. A nationally recognized speaker, author and
thought leader in his field, Mr. Goudzwaard is one of less than a
thousand fellows in the American College of Medical Practice
Executives. As principle consultant for HealthConnectors, he has
led multi-level project teams in the portfolio expansion of
ancillary services. His expertise has been sought as an advisory
board member for multiple mid-range healthcare organizations.
On the national level, Mr. Goudzwaard has served as President
and Chairman of the Western Region for the Medical Group Management
Association (MGMA).
Prior to joining NuGenerex, Mr. Goudzwaard served as an
executive in a variety of healthcare settings including hospital,
employed physician-based practices, and private practices. His
breadth of operational and financial experience spans several roles
including Chief Operating Officer (COO) of a large specialty
orthopedic and spine conglomerate and Chief Executive Officer (CEO)
of a gastroenterology practice that had 17 locations, 5 Ambulatory
Surgery Centers along with an Anesthesia and Pathology practice,
giving him an extensive background to lead the MSO operations for
NuGenerex.
Mr. Goudzwaard holds an undergraduate degree from the University
of Wyoming and a Master of Science in Health Administration from
the University of Colorado.
“Growth and diversification are key to success within the
healthcare landscape,” said Mr. Goudzwaard. “I welcome the
opportunity to build NuGenerex into a new kind of healthcare
company that enhances the physician patient experience with a range
of ancillary healthcare services that offer new business
opportunities for physician practices to improve outcomes through
patient-centric care.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding
company with end-to-end solutions for patient-centric care from
rapid diagnosis through delivery of personalized therapies. Generex
is building a new kind of healthcare company that extends beyond
traditional models providing support to physicians in an MSO
network, and ongoing relationships with patients to improve the
patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology
assets, medical devices, and diagnostics, the Company is focused on
an acquisition strategy of strategic businesses that complement
existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services
organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex
Distribution Solutions (NDS), integrates our MSO network with a
pharmacy network, clinical diagnostic lab, durable medical
equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking
Statements
This release and oral statements made from time to time by
Generex representatives in respect to the same subject matter may
contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan,"
"believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they
do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not
known. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities
and Exchange Commission, which should be considered together with
any forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private
Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2023 to Mar 2024